Literature DB >> 21571873

Invited commentary: the importance of prevalence in the effectiveness of a (bio)marker.

Arpita Ghosh1, Philip E Castle.   

Abstract

Metrics such as relative hazards and relative risks do not account for the prevalence of a marker over time and its relation to whether and when an outcome occurs. Uncommon markers that have good predictive values and common markers that are poorly predictive may not be (clinically) useful in predicting disease and other health outcomes. Recent work by Little et al. (Am J Epidemiol. 2011;173(12):1380-1387) highlights the development of a new method that considers both factors in predicting outcomes. Measures that incorporate both marker prevalence and predictive values and therefore are measures of "effectiveness" may be broadly helpful in deciding which markers or exposures are useful in disease screening or should be targeted by health interventions.

Mesh:

Substances:

Year:  2011        PMID: 21571873      PMCID: PMC3145395          DOI: 10.1093/aje/kwr016

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  12 in total

Review 1.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

Authors:  Margaret Sullivan Pepe; Holly Janes; Gary Longton; Wendy Leisenring; Polly Newcomb
Journal:  Am J Epidemiol       Date:  2004-05-01       Impact factor: 4.897

2.  The impact of a prevention effort on the community.

Authors:  Sholom Wacholder
Journal:  Epidemiology       Date:  2005-01       Impact factor: 4.822

3.  Cumulative association of five genetic variants with prostate cancer.

Authors:  S Lilly Zheng; Jielin Sun; Fredrik Wiklund; Shelly Smith; Pär Stattin; Ge Li; Hans-Olov Adami; Fang-Chi Hsu; Yi Zhu; Katarina Bälter; A Karim Kader; Aubrey R Turner; Wennuan Liu; Eugene R Bleecker; Deborah A Meyers; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Jianfeng Xu; Henrik Grönberg
Journal:  N Engl J Med       Date:  2008-01-16       Impact factor: 91.245

4.  Genetics of reproductive lifespan.

Authors:  Patricia Hartge
Journal:  Nat Genet       Date:  2009-06       Impact factor: 38.330

5.  A method for longitudinal prospective evaluation of markers for a subsequent event.

Authors:  Roderick J Little; Matheos Yosef; Bin Nan; Siobán D Harlow
Journal:  Am J Epidemiol       Date:  2011-05-13       Impact factor: 4.897

6.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 7.  Human papillomavirus and cervical cancer.

Authors:  Mark Schiffman; Philip E Castle; Jose Jeronimo; Ana C Rodriguez; Sholom Wacholder
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

Review 8.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis.

Authors:  Jill Koshiol; Lisa Lindsay; Jeanne M Pimenta; Charles Poole; David Jenkins; Jennifer S Smith
Journal:  Am J Epidemiol       Date:  2008-05-15       Impact factor: 4.897

9.  HPV vaccination in women aged 24-45 years.

Authors:  Diane Solomon; Phil Castle; Allan Hildesheim; Hormuzd A Katki; Mark Schiffman; Sholom Wacholder
Journal:  Lancet       Date:  2009-10-10       Impact factor: 79.321

10.  Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study.

Authors:  Philip E Castle; Ana Cecilia Rodríguez; Robert D Burk; Rolando Herrero; Sholom Wacholder; Mario Alfaro; Jorge Morales; Diego Guillen; Mark E Sherman; Diane Solomon; Mark Schiffman
Journal:  BMJ       Date:  2009-07-28
View more
  1 in total

1.  Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality.

Authors:  Mohammadreza Bozorgmanesh; Farzad Hadaegh; Farhad Sheikholeslami; Arash Ghanbarian; Fereidoun Azizi
Journal:  Cardiovasc Diabetol       Date:  2012-06-15       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.